Skip to main content

Evolution of Drug Discovery Process Prompts Society for Biomolecular Screening to Change Name

NEW YORK, Sept. 20 (GenomeWeb News) - The Society for Biomolecular Screening has changed its name to the Society for Biomolecular Sciences, and will now support such areas as ADME-Tox and target discovery, SBS said today.

 

The 11-year-old nonprofit organization decided to make the change following a vote of the membership.

 

"The name change reflects the evolution of a more integrated drug discovery process," Al Kolb, president of SBS, said in a statement.

 

"The society will continue to support traditional screening sciences," Kolb said. "In addition to this core discipline, SBS will reach out to other areas of drug discovery, such as [ADME-Tox] and target discovery, that are becoming more closely linked with high-throughput screening."

 

SBS has more than 2,000 members representing more than 30 countries, 400 companies, and 40 universities. It publishes the Journal of Biomolecular Screening, which will not change its name.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.